Publications

Detailed Information

Tauroursodeoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stress

DC Field Value Language
dc.contributor.authorLee, Yeon Yi-
dc.contributor.authorHong, Shin Hee-
dc.contributor.authorLee, Ye Jin-
dc.contributor.authorChung, Sung Soo-
dc.contributor.authorPark, Sang Gyu-
dc.contributor.authorPark, Kyong Soo-
dc.contributor.authorJung, Hye Seung-
dc.date.accessioned2012-05-25T06:51:24Z-
dc.date.available2012-05-25T06:51:24Z-
dc.date.issued2010-07-09-
dc.identifier.citationBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS; Vol.397 4; 735-739ko_KR
dc.identifier.issn0006-291X-
dc.identifier.urihttps://hdl.handle.net/10371/76480-
dc.description.abstractThe exposure to acute or chronic endoplasmic reticulum (ER) stress has been known to induce dysfunction of islets, leading to apoptosis. The reduction of ER stress in islet isolation for transplantation is critical for islet protection. In this study, we investigated whether tauroursodeoxycholate (TUDCA) could inhibit ER stress induced by thapsigargin, and restore the decreased glucose stimulation index of islets. In pig islets, thapsigargin decreased the insulin secretion by high glucose stimulation in a time-dependent manner (1 h, 1.35 +/- 0.16: 2 h, 1.21 +/- 0.13; 4 h, 1.17 +/- 0.16 vs. 0 h, 1.81 +/- 0.15, n = 4, p < 0.05. respectively). However, the treatment of TUDCA restored the decreased insulin secretion index induced by thapsigargin (thapsigargin, 1.25 +/- 0.12 vs. thapsigargin + TUDCA, 2.13 +/- 0.19, n = 5, p < 0.05). Furthermore, the culture of isolated islets for 24 h with TUDCA significantly reduced the rate of islet regression (37.4 +/- 5.8% vs. 14.5 +/- 6.4%, n = 12, p < 0.05). The treatment of TUDCA enhanced ATP contents in islets (27.2 +/- 3.2 pmol/20IEQs vs. 21.7 +/- 2.8 pmol/20IEQs, n = 9, p < 0.05). The insulin secretion index by high glucose stimulation is also increased by treatment of TUDCA (2.42 +/- 0.15 vs. 1.92 +/- 0.12, n = 12, p < 0.05). Taken together, we suggest that TUDCA could be a useful agent for islet protection in islet isolation for transplantation. (C) 2010 Elsevier Inc. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCEko_KR
dc.subjectDiabetes mellitusko_KR
dc.subjectInsulinko_KR
dc.subjectIsletsko_KR
dc.subjectER stressko_KR
dc.subjectApoptosisko_KR
dc.titleTauroursodeoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stressko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이연이-
dc.contributor.AlternativeAuthor홍신희-
dc.contributor.AlternativeAuthor이예진-
dc.contributor.AlternativeAuthor정성수-
dc.contributor.AlternativeAuthor정혜승-
dc.contributor.AlternativeAuthor박상규-
dc.contributor.AlternativeAuthor박경수-
dc.identifier.doi10.1016/j.bbrc.2010.06.022-
dc.citation.journaltitleBIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS-
dc.description.citedreferenceOkamoto A, 2010, BIOCHEM BIOPH RES CO, V394, P42, DOI 10.1016/j.bbrc.2010.02.065-
dc.description.citedreferencePark SG, 2010, TRANSPL INT, V23, P325, DOI 10.1111/j.1432-2277.2009.00987.x-
dc.description.citedreferenceHua YA, 2010, J CARDIOVASC PHARM, V55, P49-
dc.description.citedreferenceLefebvre P, 2009, PHYSIOL REV, V89, P147, DOI 10.1152/physrev.00010.2008-
dc.description.citedreferenceGurzov EN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003030-
dc.description.citedreferenceNoguchi H, 2008, TRANSPL P, V40, P379, DOI 10.1016/j.transproceed.2008.01.055-
dc.description.citedreferenceKim JH, 2007, XENOTRANSPLANTATION, V14, P60, DOI 10.1111/j.1399-3089.2006.00364.x-
dc.description.citedreferenceMaeda K, 2006, MOL PHARMACEUT, V3, P70, DOI 10.1021/mp050063u-
dc.description.citedreferenceOSCAN U, 2006, SCIENCE, V313, P1137-
dc.description.citedreferenceIshii S, 2005, TRANSPLANT P, V37, P3499, DOI 10.1016/j.transproceed.2005.09.134-
dc.description.citedreferenceNoguchi H, 2005, AM J TRANSPLANT, V5, P1848, DOI 10.1111/j.1600-6143.2005.00985.x-
dc.description.citedreferenceMatsumoto S, 2005, LANCET, V365, P1642, DOI 10.1016/S0140-6736(05)66383-0-
dc.description.citedreferenceContreras JL, 2003, TRANSPLANT INT, V16, P537, DOI 10.1007/s00147-003-0619-x-
dc.description.citedreferenceMakishima M, 2002, SCIENCE, V296, P1313-
dc.description.citedreferenceXIE Q, 2002, HEPATOLOGY, V36, P592-
dc.description.citedreferenceAlpini GP, 2001, HEPATOLOGY, V34, P868-
dc.description.citedreferenceEjiri S, 2001, TRANSPLANTATION, V71, P721-
dc.description.citedreferenceXie W, 2001, P NATL ACAD SCI USA, V98, P3375-
dc.description.citedreferenceShapiro AMJ, 2000, NEW ENGL J MED, V343, P230-
dc.description.citedreferenceBenz C, 2000, EUR J CLIN INVEST, V30, P203-
dc.description.citedreferenceRosenberg L, 1999, SURGERY, V126, P393-
dc.description.citedreferenceCaraher EM, 1999, J ENDOCRINOL, V162, P143-
dc.description.citedreferenceMakishima M, 1999, SCIENCE, V284, P1362-
dc.description.citedreferenceParks DJ, 1999, SCIENCE, V284, P1365-
dc.description.citedreferenceWang HB, 1999, MOL CELL, V3, P543-
dc.description.citedreferenceInvernizzi P, 1999, HEPATOLOGY, V29, P320-
dc.description.citedreferenceMarchesa P, 1997, AM J GASTROENTEROL, V92, P1285-
dc.description.citedreferenceBaumgartner U, 1996, DIGEST DIS SCI, V41, P250-
dc.description.citedreferenceShekels LL, 1996, J LAB CLIN MED, V127, P57-
dc.description.citedreferencePONGRACZ J, 1995, INT J CANCER, V61, P35-
dc.description.citedreferenceBEUERS U, 1993, J CLIN INVEST, V92, P2984-
dc.description.citedreferenceCRAVEN PA, 1986, CANCER RES, V46, P5754-
dc.description.citedreferenceDERUBERTIS FR, 1984, J CLIN INVEST, V74, P1614-
dc.description.tc7-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share